Adi Mor

1.4k total citations
32 papers, 1.1k citations indexed

About

Adi Mor is a scholar working on Immunology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Adi Mor has authored 32 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 8 papers in Molecular Biology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Adi Mor's work include Immune Cell Function and Interaction (8 papers), Liver Diseases and Immunity (6 papers) and T-cell and B-cell Immunology (6 papers). Adi Mor is often cited by papers focused on Immune Cell Function and Interaction (8 papers), Liver Diseases and Immunity (6 papers) and T-cell and B-cell Immunology (6 papers). Adi Mor collaborates with scholars based in Israel, United Kingdom and United States. Adi Mor's co-authors include Jacob George, Gad Keren, Galia Luboshits, Jeremy Ben‐Shoshan, Arnon Afek, David Planer, Shula Metzger, Tova Chajek-Shaul, Ardon Rubinstein and Yoel Kloog and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and International Journal of Molecular Sciences.

In The Last Decade

Adi Mor

30 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Adi Mor Israel 15 604 193 192 181 164 32 1.1k
Alda Corrado Italy 13 303 0.5× 240 1.2× 153 0.8× 230 1.3× 64 0.4× 30 1.3k
Yutaka Kurebayashi Japan 16 588 1.0× 356 1.8× 146 0.8× 401 2.2× 249 1.5× 42 1.3k
A. Beham Germany 20 292 0.5× 354 1.8× 113 0.6× 285 1.6× 111 0.7× 69 1.3k
Aggelos Banos Greece 16 554 0.9× 288 1.5× 143 0.7× 150 0.8× 108 0.7× 38 950
Rafia S. Al‐Lamki United Kingdom 17 306 0.5× 410 2.1× 83 0.4× 120 0.7× 127 0.8× 22 1.1k
A Fukatsu Japan 20 324 0.5× 273 1.4× 81 0.4× 139 0.8× 66 0.4× 41 1.1k
Elsie Oppermann Germany 19 184 0.3× 304 1.6× 166 0.9× 211 1.2× 115 0.7× 58 997
Margherita Gigante Italy 21 362 0.6× 440 2.3× 81 0.4× 244 1.3× 176 1.1× 38 1.2k
Akihiko Gotoh Japan 24 444 0.7× 644 3.3× 128 0.7× 369 2.0× 65 0.4× 121 1.8k
Wenxin Huang Sweden 13 438 0.7× 565 2.9× 134 0.7× 99 0.5× 66 0.4× 23 1.0k

Countries citing papers authored by Adi Mor

Since Specialization
Citations

This map shows the geographic impact of Adi Mor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adi Mor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adi Mor more than expected).

Fields of papers citing papers by Adi Mor

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adi Mor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adi Mor. The network helps show where Adi Mor may publish in the future.

Co-authorship network of co-authors of Adi Mor

This figure shows the co-authorship network connecting the top 25 collaborators of Adi Mor. A scholar is included among the top collaborators of Adi Mor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adi Mor. Adi Mor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bowlus, Christopher L., Douglas Thorburn, Stephen T. Barclay, et al.. (2025). Nebokitug, an Anti-chemokine (C-C Motif) Ligand 24 Monoclonal Antibody, in Patients With Primary Sclerosing Cholangitis: A Phase 2 Study. The American Journal of Gastroenterology.
2.
Lorenzis, Enrico De, Adi Mor, Rebecca L. Ross, et al.. (2024). Serum CCL24 as a Biomarker of Fibrotic and Vascular Disease Severity in Systemic Sclerosis. Arthritis Care & Research. 76(9). 1269–1277. 4 indexed citations
3.
Aricha, Revital, Matthew Frankel, John M. Lawler, et al.. (2024). Machine Learning Identifies Key Proteins in Primary Sclerosing Cholangitis Progression and Links High CCL24 to Cirrhosis. International Journal of Molecular Sciences. 25(11). 6042–6042. 4 indexed citations
4.
Mor, Adi, Scott L. Friedman, Sharon Hashmueli, et al.. (2024). Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies. Drug Safety. 47(9). 869–881. 8 indexed citations
5.
Aricha, Revital, Inbal Mishalian, Matthew Frankel, et al.. (2024). The Role of CCL24 in Primary Sclerosing Cholangitis: Bridging Patient Serum Proteomics to Preclinical Data. Cells. 13(3). 209–209. 8 indexed citations
6.
7.
Barashi, Neta, Sharon Hashmueli, Jacob George, et al.. (2020). A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage. JHEP Reports. 2(1). 100064–100064. 42 indexed citations
8.
Mor, Adi, Neta Barashi, Mirko Manetti, et al.. (2019). Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis. Annals of the Rheumatic Diseases. 78(9). 1260–1268. 49 indexed citations
9.
Shor, R, Amit Tirosh, Rikardo Krakover, et al.. (2012). 25 hydroxyvitamin D levels in patients undergoing coronary artery catheterization. European Journal of Internal Medicine. 23(5). 470–473. 15 indexed citations
10.
Mor, Adi, et al.. (2010). Ras inhibition attenuates pancreatic cell death and experimental type 1 diabetes: Possible role of regulatory T cells. European Journal of Pharmacology. 643(1). 139–144. 11 indexed citations
11.
Mor, Adi, et al.. (2010). The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice. Journal of Neuroimmunology. 229(1-2). 192–203. 19 indexed citations
12.
Afek, Arnon, Sofia Maysel-Auslender, Adi Mor, et al.. (2009). Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice. Microvascular Research. 77(3). 364–369. 41 indexed citations
13.
Mor, Adi, Yoel Kloog, Gad Keren, & Jacob George. (2009). Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice. European Journal of Pharmacology. 616(1-3). 301–305. 9 indexed citations
14.
Mor, Adi, Gad Keren, Yoel Kloog, & Jacob George. (2008). N‐Ras or K‐Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells. European Journal of Immunology. 38(6). 1493–1502. 27 indexed citations
15.
Mausner-Fainberg, Karin, Galia Luboshits, Adi Mor, et al.. (2007). The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis. 197(2). 829–839. 162 indexed citations
16.
Drory, Omri, Adi Mor, Felix Frolow, & Nathan Nelson. (2004). Expression, crystallization and phasing of vacuolar H+-ATPase subunit C (Vma5p) ofSaccharomyces cerevisiae. Acta Crystallographica Section D Biological Crystallography. 60(10). 1906–1909. 5 indexed citations
17.
Rapoport, Micha J., et al.. (1999). Decreased expression of the p21ras stimulatory factor hSOS in PBMC from inactive SLE patients. Lupus. 8(1). 24–28. 14 indexed citations
18.
19.
Rapoport, Micha J., Lola Weiss, Adi Mor, et al.. (1996). Prevention of autoimmune diabetes by linomide in nonobese diabetic (NOD) mice is associated with up-regulation of the TCR-mediated activation of p21(ras). The Journal of Immunology. 157(10). 4721–4725. 15 indexed citations
20.
Szeinberg, Amir, et al.. (1966). “Band X” isozyme of lactic dehydrogenase in pathological spermatogenesis. Life Sciences. 5(13). 1233–1238. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alda Corrado Breakdown of academic impact, for papers by Yutaka Kurebayashi Breakdown of academic impact, for papers by A. Beham Breakdown of academic impact, for papers by Aggelos Banos Breakdown of academic impact, for papers by Rafia S. Al‐Lamki Breakdown of academic impact, for papers by A Fukatsu Breakdown of academic impact, for papers by Elsie Oppermann Breakdown of academic impact, for papers by Margherita Gigante Breakdown of academic impact, for papers by Akihiko Gotoh Breakdown of academic impact, for papers by Wenxin Huang
Rankless by CCL
2026